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cNuclear Medicine and PET Centre, Mount Elizabeth Hospital, SingaporeAbstractIntroduction: To determine the incidence of fluorine-18-fluorodeoxyglucose (FDG) avid thyroid incidentalomas detected on positron
emission tomography (PET) with integrated computed tomography (CT), and correlate the FDGePET-CT findings to cytology.
Methods: A total of 942 FDGePET-CT reports were retrospectively reviewed. Patients with FDG-avid thyroid incidentalomas were further
reviewed for correlative cytology.
Results: The incidence of FDG-avid thyroid incidentalomas is 2.2%. Thyroid malignancies were identified in 3 of 6 patients who underwent
cytologic correlation, with a positive predictive value of 50% (95% confidence interval, 14%-86%). The mean maximum standardized uptake
values of benign and malignant FDG-avid thyroid incidentalomas were 5.6 and 6.6, respectively.
Conclusion: A FDG-avid thyroid incidentaloma may predict underlying malignancy. Cytologic assessment should be considered for
FDG-avid thyroid incidentalomas.ResumeIntroduction : Determiner l’incidence d’incidentalomes thyro€ıdiens avides au 18F fluorodesoxyglucose (FDG) deceles par tomographie par
emission de positons (TEP) avec tomodensitometrie (TDM) et etablir un lien entre les conclusions de TEP-TDM-FDG et la cytologie.
Methodes : Un total de 942 TEP-TDM-FDG ont ete examines retrospectivement. Les patients presentant des incidentalomes thyro€ıdiens
avides pour le 18F FDG ont fait l’objet d’un examen approfondi aux fins de correlation cytologique.
Resultats : L’incidence d’incidentalomes thyro€ıdiens avides au 18F FDG est de 2,2 %. Des tumeurs thyro€ıdiennes ont ete relevees chez 3 des
6 patients qui ont fait l’objet d’un depistage, avec une valeur predictive de 50 % (intervalle de confiance de 95 %, de 14 % a 86 %). Les
valeurs de fixation normalisees moyennes maximales des incidentalomes thyro€ıdiens avides au 18F FDG benins et malins etaient de 5,6 et 6,6
respectivement.
Conclusion : Un incidentalome thyro€ıdien avide au 18F-FDG peut indiquer une malignite sous-jacente. Un examen cytologique devrait e^tre
envisage dans le cas d’un incidentalome thyro€ıdien avide au 18F-FDG.
 2012 Canadian Association of Radiologists. All rights reserved.
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Thyroid incidentalomas are thyroid lesions detected emission tomography (PET) with integrated computed
during imaging for nonthyroid disease [1,2]. Whole-
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tissue.
With the increasing use of FDGePET-CT imaging, FDG-
avid thyroid incidentalomas are becoming more common.
The reported incidence of FDG-avid thyroid incidentalomas
in patients undergoing FDG-PETor PET/CT for other cancers
ranges from 1.1%-4.8%, with positive predictive values
for underlying thyroid malignancy between 27.8% and
74% [3e7]. Thyroid malignancies incidentally detected on
FDG-PET have also been reported to have a high rate of
unfavorable prognostic features and may be more aggressive
[8]. For these reasons, current clinical practice guidelines
have recommended further assessment for FDG-avid thyroid
incidentalomas [9]. We aim to evaluate the incidence of FDG-
avid thyroid incidentalomas at our institution and to compare
the FDGePET-CT findings with correlative cytology.
Methods
From April 2006 to March 2007, at the Department of
Nuclear Medicine and PET, Singapore General Hospital,
a total of 952 FDGePET-CT scans were performed for
cancer-related indications. Ten patients with a known history
of primary thyroid malignancies were excluded. FDGePET-
CT reports of all remaining 942 patients were retrospectively
reviewed.
All the scans were performed on a dedicated PET-CT
scanner (Siemens Biograph LSO, Erlangen, Germany).
FDG-PET imaging was acquired from the skull vertex to the
femur over 7 bed positions at 3 minutes each. Unenhanced CT
(single-slice, 5-mm slice thickness, 110 mAs, 130 kV) was
obtained for attenuation correction and anatomic correlation.
Patient preparation involved 6 hours of fasting and a serum
glucose level below 180 mg/dL (10 mmol/L) before FDG
injection. The administered FDG activity was estimated
empirically and ranged between 333 and 444MBq (9-12mCi).
No attempt was made to adjust the maximum standardized
uptake values (SUVmax) by blood glucose levels or recovery
coefficients. FDGePET-CT images were reviewed in the
coronal, transaxial, and sagittal planes by 2 nuclear medicine
physicians (Y.H.K., S.C.O., or A.K.P.), and any disagreement
was resolved by consensus. The CT component was inter-
preted in cooperation with a diagnostic radiologist.
A FDG-avid thyroid incidentaloma was defined as focal
unilateral thyroid FDG uptake higher than the background
thyroid bed and surrounding blood pool by visual assess-
ment, regardless of any underlying lesions seen on CT. This
definition was applied by all PET-CT reporting doctors at our
institution. For this study, only the scan reports were
reviewed, not the actual images.
FDGePET-CT reports were reviewed for any mention of
thyroid incidentalomas, regardless of FDG avidity. Patients
reported to have FDG-avid thyroid incidentalomas had their
medical records further reviewed for correlative cytology, up
to 3 years after FDGePET-CT. The patients and their
primary physicians were not contacted during this study. The
decision on whether to proceed with cytology was at thediscretion of the primary physician, who assessed the need in
context of the patient’s existing cancer illness. Patients with
diffuse thyroid FDG uptake were not further analysed,
because diffuse FDG uptake is usually due to thyroiditis and
generally is not associated with an increased risk of thyroid
malignancy [4,6,9]. The SUVmax of FDG-avid thyroid
incidentalomas were compared with the correlative cytologic
findings. The results were tabulated and analysed by standard
noncommercial statistical software.
Results
FDGePET-CT scan reports of 942 patients were
reviewed. Thyroid incidentalomas were reported in 66
patients (7.0%). Twenty-one of these 66 patients had FDG-
avid thyroid incidentalomas (31.8%); the remaining 45
patients had noneFDG-avid thyroid incidentalomas detected
on the CT component. The overall incidence of FDG-avid
thyroid incidentalomas was 2.2% (21 of 942 patients).
Follow-up data for the 45 cases of noneFDG-avid thyroid
incidentalomas were not reviewed.
Six patients underwent further cytologic evaluation by
fine needle aspiration. Malignancies were identified in
3 patients: 2 papillary thyroid carcinomas (Figure 1) and
1 medullary thyroid carcinoma (Figure 2). All 3 patients with
malignant cytology underwent thyroid surgery, and the final
diagnoses were confirmed on histopathology. The other
3 patients yielded benign cytologic findings: 1 lymphocytic
thyroiditis and 2 nodular goiters (Figure 3). The patient with
lymphocytic thyroiditis showed interval reduction in FDG
activity in a FDGePET-CT 1 month later. 1 patient with
nodular goiter showed stable FDGePET-CT findings 2 years
later. The remaining patient with nodular goiter had no
further follow-up. The results are summarized in Table 1.
The positive predictive value of FDG-avid thyroid inci-
dentalomas for underlying thyroid malignancy was 50%
(95% confidence interval, 14%-86%; 3 of 6 patients). The
mean SUVmax of benign and malignant FDG-avid thyroid
incidentalomas were 5.6 and 6.6, respectively, which may
suggest a trend for FDG-avid thyroid incidentalomas with
higher SUVmax to be malignant, although the differences
did not reach statistical significance in our small group of
6 patients (P ¼ .40, Mann-Whitney U test).
Discussion
With the increasing use of whole-body FDGePET-CT,
FDG-avid thyroid incidentalomas are being detected more
frequently. Our study found the incidence of FDG-avid
thyroid incidentalomas among patients with other primary
malignancies to be 2.2% (21 of 942 patients) and the positive
predictive value for underlying thyroid malignancy to be
50% (3 of 6 patients), in keeping with the published medical
literature [3e7]. Are et al [8] found that thyroid malignan-
cies detected incidentally on FDG-PET have a high rate of
unfavorable prognostic features and are likely to be more
aggressive. We, therefore, recommend cytologic assessment
Figure 1. Fluorine-18-fluorodeoxyglucoseepositron emission tomographyecomputed tomography (CT) with corresponding CT images of right thyroid lobe
incidentaloma (arrows) in transaxial (A, B) and coronal (C, D) planes. Postoperative histopathology was papillary thyroid carcinoma. This figure is available in
colour online at http://carjonline.org/.
Figure 2. Fluorine-18-fluorodeoxyglucoseepositron emission tomographyecomputed tomography (CT), with corresponding CT images of right thyroid lobe
incidentaloma (arrows) in transaxial (A, B) and coronal (C, D) planes. Hypermetabolic right cervical lymph nodes also can be seen. Postoperative histopa-
thology was medullary thyroid carcinoma with right cervical nodal metastasis. This figure is available in colour online at http://carjonline.org/.
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Figure 3. Fluorine-18-fluorodeoxyglucose (FDG)epositron emission tomography (PET)ecomputed tomography (CT) with corresponding CT images of right
thyroid lobe incidentaloma (arrows) in transaxial (A, B) and coronal (C, D) planes. Fine needle aspiration cytology showed nodular goiter. This lesion was
stable in a FDGePET-CT 2 years later. This figure is available in colour online at http://carjonline.org/.
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mas due to the risk of underlying thyroid malignancy.
The diagnostic accuracy of FDG-PET or PET-CT in the
assessment of thyroid nodules for malignancy is currently
indeterminate, with wide-ranging sensitivities and specific-
ities reported in literature [10e13]. Notably, these were all
small studies with varying methodologies and different
definitions for FDG avidity [10e13]. In our study, despite
malignant FDG-avid thyroid incidentalomas having a higher
mean SUVmax than benign incidentalomas, the differences
did not reach statistical significance. Overall, our findings are
in keeping with current clinical practice guidelines that do
not recommend the routine use of FDG-PET or PET-CT in
the assessment of thyroid nodules [9]. There also is no
consensus on the utility of the standardized uptake value as
a predictor of malignancy in FDG-avid thyroid incidentalo-
mas [1e3,5,6,11,13e15], which may be related to theTable 1
Summary of 6 patients with FDG-avid thyroid incidentalomas and correlative cy
Age, y Sex FDGePET-CT indication
Incidentaloma,
SUVmax Cytologi
69 F Colon carcinoma 6.8 Nodular
76 M Gastric DLBCL 4.9 Nodular
78 F Gallbladder carcinoma 5.2 Lympho
67 F Endometrial neuroendocrine tumour 8.8 Papillary
75 M Colon carcinoma 5.6 Papillary
63 M Elevated CEA for investigation 5.5 Medulla
CEA ¼ carcinoembryonic antigen; CT ¼ computed tomography; DLBCL ¼ diff
not applicable; PET ¼ positron emission tomography; SUVmax ¼ maximum stobservation that many well-differentiated thyroid cancers do
not show increased FDG uptake and, therefore, may not be
detectable on PET [16e19]. At a cellular level, it had been
reported that GLUT1 transporter expression in thyroid
neoplasms is closely related to the grade of malignancy:
GLUT1 transporter was poorly expressed in well-
differentiated thyroid tumours, although highly expressed
in anaplastic thyroid carcinoma [20e22]. We speculate that
the lack of diagnostic accuracy of FDG avidity as an indi-
cation of thyroid malignancy could be due to heterogeneous
GLUT1 transporter expression among different subtypes of
thyroid cancer.
Limitations
This study was retrospective, and there was no contact
with the patients or their primary physicians. Hence, we weretology
c diagnosis Surgery Final histopathology
goiter No N/A
goiter No N/A
cytic thyroiditis No N/A
thyroid carcinoma Total thyroidectomy Papillary thyroid carcinoma
thyroid carcinoma Hemi-thyroidectomy Papillary thyroid carcinoma
ry thyroid carcinoma Total thyroidectomy Medullary thyroid carcinoma
use large B-cell lymphoma; FDG ¼ fluorine-18-fluorodeoxyglucose; N/A ¼
andardized uptake value.
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with FDG-avid thyroid incidentalomas did not have a record
of follow-up cytologic assessment. Possibilities may include
the following: a decision by the primary physician not to
perform cytology, cytology performed at other medical
institutions, or lost to follow-up. Only 6 patients underwent
correlative cytology, which limited the statistical power of
this study. These factors preclude any definitive conclusions
to be made from this study.
Conclusion
The incidence of FDG-avid thyroid incidentalomas
among patients with other primary malignancies was 2.2%,
with a positive predictive value of 50% for underlying
thyroid malignancy. There may be a trend for FDG-avid
thyroid incidentalomas with higher SUVmax to be malig-
nant. Follow-up cytologic assessment should be considered
for FDG-avid thyroid incidentalomas.
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